Entrada plans to initiate clinical testing of ENTR-601-44 in Duchenne MD patients amenable to exon 44 skipping later this year.

The Elevate-44-201 study is a global, two-part, randomized, double-blind placebo-controlled phase 1/2 study evaluating the ...

What is the best career fit for me? Take our assessment now. Finding your dream job starts with knowing what makes you the way you are. Simple Statements that relate to you. Unique Be yourself ...

Roche announces positive results from EMBARK phase III study of Elevidys in ambulatory individuals with DMD: Basel Tuesday, January 28, 2025, 11:00 Hrs [IST] Roche announced posit ...

Riding recent momentum in the Duchenne muscular dystrophy space, Capricor Therapeutics, Wave Life Sciences, Regenxbio and ...

While the last decade has brought considerable progress for patients with DMD, substantial unmet need remains. Several ...

Dyne Therapeutics is a clinical stage biotech concern with just over $700 million of cash on its balance sheet. Learn more about DYN stock here.

Becker muscular dystrophy tends to appear later than the most common form of the disease, Duchenne MD (DMD). Symptoms may appear as late as age 25. Becker MD also progresses slower than DMD and is ...

TEMPE, Ariz., Jan. 16, 2025 /PRNewswire/ -- DMD Systems Recovery, LLC (DMD), a leader in Reuse First™ IT Asset Disposition (ITAD) services and a Certified B Corporation, has been ranked #27 ...

Duchenne muscular dystrophy (DMD) is the most common type. It’s caused by flaws in the gene that controls how the body keeps muscles healthy. The disease almost always affects boys, and symptoms ...

INS1201 represents the first application of Insmed’s targeted AAV delivery platform in DMD. Credit: JHVEPhoto / Shutterstock. Duchenne muscular dystrophy (DMD) is a rare genetic disorder that is ...

Lucy Notarantonio is Newsweek's Senior Lifestyle and Trends Reporter, based in Birmingham, UK. Her focus is trending stories and human interest features ranging from health, pets and travel.